As the second major signalling cascade involved in cancer pathogenesis and one of the most frequently mutated pathways in all human cancers, the BRAF/MEK/ERK pathway has been a major target for clinical therapeutic development, especially in cancers where BRAF mutations are common, such as in melanoma and thyroid cancer. The gene discussed is MAP2K7; the disease is melanoma.